NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Eversept Partners LP

Eversept Partners LP trimmed its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 10.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 275,362 shares of the company's stock after selling 31,995 shares during the period. Eversept Partners LP owned approximately 0.30% of NewAmsterdam Pharma worth $7,077,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Bain Capital Life Sciences Investors LLC grew its stake in NewAmsterdam Pharma by 2.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company's stock valued at $275,481,000 after acquiring an additional 245,197 shares during the last quarter. Jennison Associates LLC increased its stake in NewAmsterdam Pharma by 291.9% in the fourth quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after purchasing an additional 2,978,263 shares during the last quarter. Wellington Management Group LLP lifted its position in NewAmsterdam Pharma by 2,410.4% during the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after buying an additional 2,222,900 shares during the period. Capital International Investors acquired a new stake in NewAmsterdam Pharma in the 4th quarter worth about $53,007,000. Finally, Alliancebernstein L.P. acquired a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at about $47,752,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on NAMS shares. HC Wainwright reissued a "buy" rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Needham & Company LLC restated a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Finally, UBS Group set a $41.00 price target on NewAmsterdam Pharma in a report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $43.33.

Insider Activity at NewAmsterdam Pharma

In related news, Director James N. Topper acquired 4,005 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average price of $21.02 per share, for a total transaction of $84,185.10. Following the transaction, the director now directly owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. This trade represents a 0.13 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 19.50% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Trading Up 0.3 %

NAMS stock traded up $0.05 during trading on Friday, reaching $17.52. The stock had a trading volume of 345,323 shares, compared to its average volume of 592,501. The firm has a fifty day moving average price of $19.66 and a 200 day moving average price of $21.20. The company has a market capitalization of $1.92 billion, a P/E ratio of -6.74 and a beta of -0.01. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. Sell-side analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.